초록 ▼

A method that includes introducing a catheter assembly to an obstructed region of a blood vessel lumen and recanalizing the obstructed region with the catheter assembly is disclosed. Prior to or during recanalization, a treatment agent may be delivered through the catheter assembly to a vessel regio

A method that includes introducing a catheter assembly to an obstructed region of a blood vessel lumen and recanalizing the obstructed region with the catheter assembly is disclosed. Prior to or during recanalization, a treatment agent may be delivered through the catheter assembly to a vessel region downstream to the obstructed region. The treatment agent may have a property that will inhibit reperfusion injury. Alternatively, a medical device may be introduced to an obstructed region of a blood vessel lumen and the obstructed region recanalized with the medical device. The treatment agent may be delivered to a vessel region downstream to the obstructed region. The treatment agent may include at least one of an immunosuppresant and an antioxidant. In other methods, a delivery cannula may be introduced to an unperfused region of an occluded vessel without disrupting the occlusion and the treatment agent having a property that will inhibit reperfusion injury may be delivered to the unperfused region through the delivery cannula. After delivering the treatment agent, the occluded vessel may be recanalized by advancing an angioplasty device into the occluded vessel.

대표청구항 ▼

1. A method comprising: introducing a catheter assembly to an obstructed region of a blood vessel lumen, the catheter assembly comprising a primary cannula, a fluid delivery cannula and a guidewire cannula, the fluid delivery cannula and the guidewire cannula being separate cannulas positioned withi

1. A method comprising: introducing a catheter assembly to an obstructed region of a blood vessel lumen, the catheter assembly comprising a primary cannula, a fluid delivery cannula and a guidewire cannula, the fluid delivery cannula and the guidewire cannula being separate cannulas positioned within, and extending from a proximal end to a distal end of, the primary cannula, the guidewire cannula having an outer surface positioned along, and interfacing with, an outer surface of the fluid delivery cannula such that they are side by side within the primary cannula, each of the fluid delivery cannula and the guidewire cannula having a distal end and a proximal end, wherein the distal ends of the fluid delivery cannula and the guidewire cannula are advanced through the obstructed region, and wherein the distal end of the guidewire cannula is open to the blood vessel lumen such that a guidewire advanced through the guidewire cannula and out the distal end is exposed to the blood vessel lumen, and the distal end of the fluid delivery cannula comprises a single fluid delivery port, and the single fluid delivery port is positioned distal to the distal end of the primary cannula and within a region of the blood vessel lumen downstream to the obstructed region while the proximal end of the fluid delivery cannula and the guidewire cannula are positioned external to the blood vessel;recanalizing the obstructed region with the catheter assembly; andduring recanalization, delivering a treatment agent through the fluid delivery port and into the region of the blood vessel lumen downstream to the obstructed region, the treatment agent having a property that will inhibit reperfusion injury, and the treatment agent comprises at least one of an immunosuppressant or an antioxidant. 2. The method of claim 1, wherein introducing comprises positioning the catheter assembly in a coronary sinus and delivering comprises releasing the treatment agent from the catheter assembly. 3. The method of claim 1, wherein the catheter assembly is an angioplasty catheter. 4. The method of claim 1, wherein the immunosuppressant is selected from the group consisting of corticosteroids, everolimus, rapamycin and derivatives thereof. 5. The method of claim 1, wherein the antioxidant is selected from the group consisting of ascorbic acid, proanthocyanadins, carotenoids, tocopherol, selenium, N-acetyl-carnitine, R-lipoic acid and coenzyme Q-10. 6. The method of claim 1, wherein the treatment agent further comprises a drug selected from the group consisting of cariporide, eniporide, zoniporide, nicaraven, MLN01, nicorandil, raloxifene, edaravone, adenosine and carvedilol. 7. The method of claim 6, wherein 100 percent of the drug is released over a 72 hour period. 8. The method of claim 1, wherein the treatment agent is disposed in a sustained release carrier. 9. The method of claim 8, wherein the carrier comprises particles having an average diameter on the order of 10 microns (μm) or less. 10. The method of claim 1, wherein the treatment agent is disposed in a carrier having an agent directed to a specific binding site on an endothelial cell. 11. The method of claim 1, wherein the treatment agent is disposed in a charged carrier for enhanced capillary retention. 12. A method comprising: introducing a medical device having a porous balloon to an obstructed region of a blood vessel lumen by advancing a distal end of the porous balloon through the obstructed region and into a region within the blood vessel lumen downstream of the obstructed region;recanalizing the obstructed region with the medical device; anddelivering a treatment agent through the porous balloon to the region within the blood vessel lumen downstream of the obstructed region prior to reperfusion of the region within the blood vessel lumen downstream of the obstructed region, the treatment agent comprising at least one of an immunosuppressant and an antioxidant, wherein during delivering, the porous balloon is only partially inflated to a diameter less than an inner diameter of the blood vessel lumen at the obstructed region such that, during delivery, an obstruction remains within the obstructed region and the porous balloon does not contact a blood vessel wall defining the lumen. 13. The method of claim 12, wherein introducing comprises positioning the medical device in a coronary sinus and delivering comprises infusion of the treatment agent. 14. The method of claim 12, wherein the medical device is one of an angioplasty catheter and a stent delivery catheter. 15. The method of claim 12, wherein the immunosuppressant is selected from the group consisting of corticosteroids, everolimus, rapamycin and derivatives thereof. 16. The method of claim 12, wherein the antioxidant is selected from the group consisting of ascorbic acid, proanthocyanadins, carotenoids, tocopherol, selenium, N-acetyl-carnitine, R-lipoic acid and coenzyme Q-10. 17. The method of claim 12, wherein the treatment agent is a drug selected from the group consisting of cariporide, eniporide, zoniporide, nicaraven, MLN01, nicorandil, raloxifene, edaravone, adenosine and carvedilol. 18. The method of claim 12, wherein the treatment agent is disposed in a sustained release carrier. 19. The method of claim 18, wherein 100 percent of the drug is released over a 72 hour period. 20. The method of claim 18, wherein the carrier comprises particles having an average diameter on the order of 10 microns (μm) or less. 21. The method of claim 12, wherein the treatment agent is disposed in a carrier having an agent directed to a specific binding site on an endothelial cell. 22. The method of claim 12, wherein the treatment agent is disposed in a charged carrier for enhanced capillary retention. 23. A method comprising: introducing a primary cannula, a fluid delivery cannula and a guidewire cannula to an unperfused region of an occluded vessel lumen which is downstream from the occlusion without occluding blood flow upstream to the occlusion, the guidewire cannula and the fluid delivery cannula being separate cannulas positioned within the primary cannula, the guidewire cannula having an outer surface positioned along, and interfacing with, an outer surface of the fluid delivery cannula, and each of the fluid delivery cannula and the guidewire cannula having a distal portion and a proximal portion defining a length dimension of the cannulas that extends from a distal end to a proximal end of the primary cannula, wherein an end of the distal portion of the guidewire cannula is open to the blood vessel lumen such that a guidewire advanced through the guidewire cannula and out the end of the distal portion is exposed to the blood vessel lumen, and wherein introducing comprises advancing the distal portion of each of the fluid delivery cannula and the guidewire cannula through the occlusion and to the unperfused region, wherein advancing the distal portion does not disrupt the occlusion in a manner that causes blood to be reintroduced to the unperfused region, and wherein the proximal portion of each of the fluid delivery cannula and the guidewire cannula is external to the vessel;delivering a treatment agent having a property that will inhibit reperfusion injury through the fluid delivery cannula to the unperfused region, and the treatment agent comprises at least one of an immunosuppressant or an antioxidant; andafter delivering the treatment agent, recanalizing the occluded vessel by advancing an angioplasty device into the occluded vessel to restore blood flow to the unperfused region. 24. The method of claim 23, wherein a balloon of the angioplasty device is advanced over the delivery cannula. 25. The method of claim 23, wherein the delivery cannula is removed prior to recanalizing the occluded vessel. 26. The method of claim 23, wherein the immunosuppressant is selected from the group consisting of corticosteroids, everolimus, rapamycin or derivatives thereof. 27. The method of claim 23, wherein the antioxidant is selected from the group consisting of ascorbic acid, proanthocyanadins, carotenoids, tocopherol, selenium, N-acetyl-carnitine, R-lipoic acid and coenzyme Q-10. 28. The method of claim 27, wherein the carrier comprises particles having an average diameter on the order of 10 microns (μm) or less. 29. The method of claim 23, wherein the treatment agent further comprises a drug selected from the group consisting of cariporide, eniporide, zoniporide, nicaraven, MLN01, nicorandil, raloxifene, edaravone, adenosine and carvedilol. 30. The method of claim 29, wherein 100 percent of the drug is released over a 72 hour period. 31. The method of claim 23, wherein the treatment agent is disposed in a sustained release carrier. 32. The method of claim 23, wherein the treatment agent is disposed in a carrier having an agent directed to a specific binding site on an endothelial cell. 33. The method of claim 23, wherein the treatment agent is disposed in a charged carrier for enhanced capillary retention. 34. The method of claim 23, wherein the delivery cannula comprises a diameter of 0.02 inches or less.